Physician profile
Scott E Schachter
NPI 1447230602
$311,871.05
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $204K · 2020: $69K · 2021: $35K · 2022: $4,250.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $73,126.24 | 2019 | |
| Novartis Pharmaceuticals Corporation | $46,988.35 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $46,712.49 | 2019-2020 | |
| Allergan, INC. | $34,916.67 | 2019-2021 | |
| Sight Sciences, INC. | $28,594.36 | 2019-2021 | |
| Lumenis, INC | $22,070.73 | 2019-2020 | |
| Maculogix, INC. | $19,055.93 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $18,072.71 | 2019-2021 | |
| Dompe US, INC. | $11,346.73 | 2019-2023 | |
| Alcon Vision LLC | $8,543.18 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,461.40 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $542.75 | 2020 | |
| Coopervision INC. | $188.77 | 2019-2020 | |
| Alcon Research LLC | $184.48 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $46.86 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Research and ownership
$42,921.50 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Schachter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.